of solid tumors. The prognostic implication of lymphovascular invasion has been explored repeatedly; in lymph node -positive breast cancer, it was reported to be a poor prognostic factor ( 4 -7 ) but with some controversy ( 8 ) . More recently, the prognostic value of lymphovascular invasion has been evaluated in patients with lymph node -negative breast cancer ( 9 -11 ) . Two studies ( 11 , 12 ) have demonstrated that the presence of lymphovascular invasion is associated with young age (<35 vs ≥ 35 years), positive lymph nodes, increasing tumor size (<0.5 vs ≥ 0.5 cm in diameter), and high malignancy grade (grade 1 vs grades 2 -3), and the proportion of patients with lymphovascular invasion has been small among patients with otherwise favorable characteristics. In the latter group, the statistical power of the analysis regarding lymphovascular invasion was relatively low, even in the few larger studies ( 9 , 11 ) .
To date, the presence of lymphovascular invasion has not been included in decision-making tools provided to assist clinicians in selecting breast cancer patients who should be treated with adjuvant therapies ( 13 -15 ) . However, in 2004, lymphovascular invasion was recognized by the St Gallen consensus conference ( 2 ) as a poor prognostic factor, albeit with some controversy, and it has not been included in the National Institutes of Health guidelines ( 3 ) .
Since 1996, the presence of lymphovascular invasion has been evaluated prospectively in all newly diagnosed patients with primary operable breast cancer in Denmark and reported to the Danish Breast Cancer Cooperative Group (DBCG) Registry. We report the prognostic impact of lymphovascular invasion in 15 000 breast cancer patients who were diagnosed from January 1, 1996, through December 31, 2002, and specifi cally examine whether the prognostic infl uence of lymphovascular invasion is similar in lowand high-risk groups.
Patients and Methods
Since the establishment of the DBCG in 1977, virtually all diagnostic and treatment units in Denmark have applied DBCG guidelines for diagnostic procedures, surgery, radiotherapy, systemic therapy, and follow-up for early-stage breast cancer. Diagnostic, therapeutic, and follow-up data have been accumulated prospectively in the DBCG Registry by the use of standardized forms ( 16 ) . The DBCG Data Center applied the same procedures for all patients, including monitoring and analysis of data, regardless of whether the patient had participated in a randomized trial.
Patients
This analysis includes women who were diagnosed with breast cancer and entered into the DBCG Registry from January 1, 1996, through December 31, 2002, and who had completely resected unilateral invasive carcinoma of the breast and no signs of distant metastasis, as determined by routine examinations (ie, physical examination, clinical chemistry, chest radiography, and other examinations as indicated). To be included in the study, patients were required to have received treatment according to DBCG guidelines as follows: a negative sentinel node biopsy or axillary clearance (level I and part of level II) in combination with breastconserving surgery or mastectomy, and radiotherapy administered to the breast following lumpectomy (48 Gy), to the chest wall following mastectomy (48 Gy) if the tumor was larger than 5 cm in diameter or was lymph node positive, and to regional lymph nodes (48 Gy) in lymph node -positive disease, all in 2-Gy fractions at five fractions per week. A 10-Gy boost in five fractions was given after breast-conserving surgery in patients younger than 50 years. Written or witnessed informed consent was required for registration in the database.
Pathological Procedures
The following characteristics were reported prospectively for each patient to the DBCG database: classification of histological type according to the World Health Organization ( 17 ) , histological grade (ductal and lobular carcinomas) according to Elston and Ellis ( 18 ) , tumor margin status, invasion into skin or deep fascia, tumor size, total number of lymph nodes identified, number of metastatic nodes, and estrogen receptor (ER) and progesterone receptor (PgR) status. Expression of ER and PgR was determined locally by immunohistochemistry, and in general, PgR expression was analyzed only if ER staining was negative. Tumors were considered hormone receptor positive if at least 10% of tumor cell nuclei were ER or PgR positive in immunostained tumor sections that were viewed using a ×40 objective ( 19 ) . The presence of lymphovascular invasion was evaluated locally in hematoxylin and eosin -stained sections, and the DBCG guidelines recommended supplementary use of an endothelial cell marker such as podoplanin, D2-40, CD34, or CD31 in the case of uncertainty about the presence of lymphovascular invasion ( 20 ) . Lymphovascular invasion was considered to be present when tumor cells were detected in an endothelial cell -lined channel in the periphery of the invasive carcinoma ( 21 ) .
CONTEXT AND CAVEATS

Prior knowledge
Although lymphovascular invasion of breast cancer has been associated with poor outcome, it is unclear whether it is an independent risk factor for recurrence.
Study design
The outcomes of survival and invasive disease among breast cancer patients in Denmark were evaluated based on the presence or absence of lymphovascular invasion.
Contribution
Lymphovascular invasion was associated with reduced survival rate and shorter time to invasive disease for patients who were at high risk of recurrence based on previously defined criteria; no association was observed for patients at low risk of recurrence.
Implications
Lymphovascular invasion was not an independent risk factor for disease recurrence in this population.
Limitations
In most of the samples, tumor invasion was detected using a general tissue staining procedure rather than a cell type -specific procedure that could have improved the accuracy. The extent of invasion, which has previously been found to be related to prognosis, was not evaluated.
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Assignment to Risk Groups and Systemic Therapies
The low-risk group, as defined by the DBCG in 2001 ( 16 ), included women aged 35 years or older who had a lymph nodenegative primary tumor not larger than 2 cm in diameter. In addition, patients in the low-risk group were required to have hormone receptor -positive tumors (ER and/or PgR positive or hormone receptor status unknown) and tumors with a favorable histology or malignancy grade, for example, grade 1 ductal carcinoma, grades 1 -2 lobular carcinoma, or a histological type other than ductal or lobular. Patients with at least one of the risk criteria defined above were prospectively assigned to the high-risk group ( 2 , 16 ) . Patients in the low-risk group did not receive adjuvant systemic therapy. During the entire study period, patients with lymph node -positive disease or tumors larger than 5 cm in diameter were strongly advised to receive systemic therapy, and the recommendation of systemic therapy was gradually introduced during the first 2 years of the study period for patients with the remaining risk criteria. Postmenopausal women with hormone receptor -positive tumors and at least one of the high-risk criteria were considered for 5 years of endocrine therapy with tamoxifen, with an aromatase inhibitor, or with the two drugs in sequence. The remaining patients in the high-risk group were considered for chemotherapy or combined chemotherapy and endocrine therapy according to their hormone receptor status.
Follow-up
Treatment-related adverse events and findings on clinical examination were recorded every 3 months during the first year after diagnosis, then every 6 months during the second through fifth years, and annually thereafter for a total of 10 years. An almost complete follow-up for survival was obtained for all patients through linkage to the Danish Central Population Registry; only six patients emigrated and were censored at the date of emigration. Hemoglobin levels, white blood cell count, and platelet count were examined on day 1 of each chemotherapy cycle. Additional biochemical tests and imaging examinations were done when indicated by existing symptoms or signs.
Statistical Analysis
The DBCG Data Center undertook central review, monitoring, and analysis of all data. Follow-up time was quantified in terms of a Kaplan -Meier estimate of potential follow-up ( 22 ) . Overall survival was calculated as the time elapsed from the date of definitive surgery until death from any cause. The invasive disease -free interval was defined as the duration of survival without invasive locoregional recurrence, distant metastases, contralateral invasive breast cancer, second primary non -breast invasive cancer, or death from any cause. Overall survival and invasive disease -free interval were analyzed using the Kaplan -Meier product-limit method, and patients with and without lymphovascular invasion were compared by using the log-rank test. The Cox proportional hazards regression model was used to assess the hazard ratios (HRs) for the invasive disease -free interval and the overall survival in patients with vs without lymphovascular invasion and to explore interactions. Factors included in the multivariable analyses were menopausal status (pre-or postmenopausal), age (<35, 35 -49, 50 -59, 60 -69, ≥ 70 years), tumor size (<21, 21 -50, >50 mm in diameter), number of positive lymph nodes (0, 1 -3, 4 -9, ≥ 10), histological type and grade (ductal grade 1, ductal grade 2 or unknown, ductal grade 3, lobular, other histological types), hormone receptor status (ER and/or PgR positive, ER and PgR negative, or unknown ), local therapy (mastectomy without radiotherapy, mastectomy with radiotherapy, breast-conserving surgery with radiotherapy), and systemic therapy (none, endocrine therapy, chemotherapy, combined chemoendocrine therapy). Cut points were selected according to prior publications from the DBCG Registry ( 23 , 24 ) . Interactions between the presence or absence of lymphovascular invasion and the covariates, positive lymph nodes, tumor size, menopausal status, ER status, systemic therapy, and risk group, were investigated in separate models by applying the Wald test and using cut points as defined in Figures 3 and 4 and previously used by the DBCG ( 24 ), except a subdivision of the high-risk group according to TNM stage ( 17 ) . The assumption of proportional hazards was assessed by Schoenfeld residuals and by including a time-dependent component for each covariate in the model. The hazard rates of histological type and grade and of hormone receptor status were not proportional, and therefore, stratification was used. Associations between lymphovascular invasion and other characteristics (excluding unknowns) were analyzed by using the 2 test. All P values are two-sided. Statistical analyses were done at the DBCG Registry with the use of SAS v8.2 statistical software (SAS Institute, Inc., Cary, NC).
Results
From January 1, 1996, through December 31, 2002, a total of 16 172 patients with operable breast cancer were registered in the DBCG Registry, and patient, tumor, and treatment characteristics were fully reported for 15 659 (97%) of those patients ( Table 1 ) . Complete follow-up for survival was achieved for all 15 659 patients. Among the 16 121 patients who could be assigned to a risk group, lymphovascular invasion was present in 2453 (15%), absent in 13 206 (82%), and not assessed in 462 (3%). The presence of lymphovascular invasion was statistically significantly associated with positive nodal status, tumor size larger than 20 mm, ductal histology, malignancy grade 2 or 3, ER negativity, and endocrine therapy and/or chemotherapy ( P < .001 for each). Among the 15 659 evaluable patients, the estimated median potential follow-up for invasive disease -free interval and overall survival was 6.4 and 7.7 years, respectively. The 5-year invasive disease -free interval rate in patients without lymphovascular invasion was 79.5% (95% confidence interval [CI] = 78.7% to 80.2%), and in patients with lymphovascular invasion, it was 54.5% (95% CI = 52.4% to 56.6%). The 5-year overall survival rates were 87.3% (95% CI = 86.7% to 87.8%) and 66.0% (95% CI = 64.1% to 67.9%) in patients without and with lymphovascular invasion, respectively. Lymphovascular invasion was associated with shorter invasive disease -free interval (HR for invasive disease = 2.48, 95% CI = 2.32 to 2.66, P < .001) and shorter overall survival (HR for death = 2.74, 95% CI = 2.55 to 2.94, P < .001).
We further assessed the prognostic implications of lymphovascular invasion separately according to risk group. In the low-risk group (n = 3271), we detected no statistically signifi cant difference in invasive disease -free interval ( Figure 1 ) or overall survival ( Figure 2 ) between patients with (n = 54) and without (n = 3217) lymphovascular invasion (HR for invasive disease = 0.84, 95% CI = 0.40 to 1.77, P = .65; and HR for death = 0.44, 95% CI = 0.14 to 1.36, P = .15). Among patients in the high-risk group, lymphovascular invasion was associated with shorter invasive disease -free interval (HR for invasive disease = 2.29, 95% CI = 2.14 to 2.45, P < .001) ( Figure 1 ) . Likewise, the absence of lymphovascular invasion was associated with a statistically signifi cant survival advantage in the high-risk group (HR for death = 2.42, 95% CI = 2.25 to 2.61, P < .001) ( Figure 2 ). At 5 years after surgery, 65.4% (95% CI = 63.5% to 67.3%) of highrisk patients with lymphovascular invasion and 85.2% (95% CI = 84.5% to 85.9%) of high-risk patients without lymphovascular invasion were alive. At 5 years after surgery, 98.1% (95% CI = 87.6% to 99.7%) of low-risk patients with lymphovascular invasion and 94.1% (95% CI = 93.2% to 94.8%) of low-risk patients without lymphovascular invasion were alive.
In a multivariable analysis that adjusted for factors that were statistically significantly associated with invasive disease -free interval (ie, age, menopausal status, tumor size, nodal status, histological type and grade, hormone receptor status, and treatment), the hazard ratio for invasive disease -free interval decreased to 1.33 (95% CI = 1.23 to 1.44, P < .001), and for overall survival, it decreased to 1.30 (95% CI = 1.20 to 1.42, P < .001). There was a statistically significant interaction between ER status and lymphovascular invasion. Patients with ER-negative tumors experienced a more pronounced influence of lymphovascular invasion on invasive disease -free interval and overall survival ( Figures 3 and 4 ) . Likewise, a statistically significant difference favoring the absence of lymphovascular invasion was seen regarding overall survival for small tumor size (<20 mm) and premenopausal status. Lymphovascular invasion was, however, consistently associated with shorter invasive disease -free interval ( Figure 3 ) and shorter overall survival ( Figure 4 ) , regardless of other tumor and patient characteristics. A statistically significant difference was demonstrated in the influence of lymphovascular invasion on overall survival between the low-and high-risk groups ( P interaction = .03; Figure 4 ). Hazard ratios (HRs) refer to adjusted-per-protocol estimates obtained in separate multivariable models. The box size is inversely proportional to the standard error (SE) of the HR, and the extending horizontal lines indicate the 95% confi dence interval (CI). ER = estrogen receptor; N Ϫ = node negative; N+ = node positive; T = tumor size; Chemo + endocrine = chemotherapy plus endocrine therapy; Chemo Ϫ endocrine = chemotherapy but no endocrine therapy; CI = confi dence interval; HR = hazard ratio.
Discussion
In this study, we examined the prognostic influence of lymphovascular invasion within a prospectively identified cohort of more than 15 000 breast cancer patients among whom lymphovascular invasion was assessed at diagnosis according to the guidelines of a cooperative group. Our results confirm that lymphovascular invasion is a marker of poor prognosis among patients with early-stage breast cancer who were classified as having an increased risk of recurrence and who received or were being considered for adjuvant systemic therapy. Among patients in the high-risk group, the shorter invasive disease -free and overall survival associated with lymphovascular invasion seemed to be identical in lymph node -negative and lymph node -positive patients. Among patients in the low-risk group, however, the presence of lymphovascular invasion was not associated with shorter invasive disease -free interval or shorter overall survival. By contrast, we found statistically significant evidence for heterogeneity in the association between lymphovascular invasion and overall survival according to risk group ( P interaction = .03), in that lymphovascular invasion was associated with worse overall survival in the high-risk group but not in the low-risk group. Our data indicate that the prognostic impact of lymphovascular invasion should be analyzed separately for patients in the lowrisk group, but because of the low prevalence of lymphovascular invasion in low-risk patients, this requires a large number of patient samples. Lymphovascular invasion was present in only 54 (1.65%) of the 3271 patients in the low-risk group. The negative prognostic infl uence of lymphovascular invasion was not statistically signifi cantly different in patients receiving adjuvant systemic therapy compared with those not receiving adjuvant therapy. A recent update of the Breast International Group (BIG) 1-98 trial indicated that the benefi cial effect of letrozole vs tamoxifen might be greater in patients with lymphovascular invasion than in those without lymphovascular invasion ( 25 ) . We were unable to analyze this relationship because the use of tamoxifen and aromatase inhibitors remains blinded for the patients included in this study who participated in the Intergroup Exemestane Study (n = 123) of sequential tamoxifen, followed by exemestane vs tamoxifen or BIG 1-98 (n = 1338) randomized trials ( 25 , 26 ) .
This study has some potential limitations. First, our assessment of lymphovascular invasion was based on the identifi cation of clusters of tumor cells within an endothelial cell -lined space and, for the most part, was performed in tumor sections that were stained with hematoxylin and eosin. The use of immunohistochemical staining with a selective endothelial cell marker such as podoplanin, D2-40, CD34, or CD31 was optional, and systematic use of such markers could potentially have improved the accuracy of detection of lymphovascular invasion ( 20 ) . Second, lymphovascular invasion may have been falsely reported because of retraction artifacts induced by fi xation of tissue and misreading of capillary blood vessels and/or may be have missed if tumor cells had obliterated the lumen of a vessel. Third, misclassifi cation could arise if the pathologists were not consistent in how they defi ned and scored lymphovascular invasion. In this study, 18 pathology laboratories reported lymphovascular invasion prospectively using a standardized form during the study period. Training and guidelines were provided to participating pathologists, but participation in an external quality control program was not mandatory; even so, some of the pathology laboratories participated in the United Kingdom National External Quality Assessment Service, and others participated in NordiQC, which is based in the Nordic countries. Fourth, the extent of lymphovascular invasion was not evaluated. Colleoni et al. ( 11 ) found that extensive lymphovascular invasion, which they defi ned as the presence of multiple foci of lymphovascular invasion in more than one tumor block as opposed to focal and moderate invasion, was associated with a worse prognosis as compared with no lymphovascular invasion. However, their analysis was restricted to lymph node -negative patients, and the patients in their study who had extensive lymphovascular invasion in the tumor made up only a small fraction (n = 31) of all patients with lymphovascular invasion (n = 178). Despite these limitations, a study performed by the European Commission Working Group on Breast Screening Pathology ( 27 ) reported a 90% agreement among 23 pathologists on the presence or absence of lymphovascular invasion when lymphovascular invasion was dichotomized into being present or absent.
The study also has several strengths. The sample size was large and included more than 15 000 breast cancer patients with at least 5 years of follow-up, and the approach was population based. Tumor characteristics were evaluated prospectively. Lymphovascular invasion was evaluated according to the guidelines of a cooperative group using standardized forms for prospective entry of data into a clinical database.
However, HER2 status was not assessed prospectively, and only 38 patients received adjuvant trastuzumab following participation in the Herceptin Adjuvant trial ( 28 ) . As previously described ( 16 ) , the use of aromatase inhibitors had not been fully implemented during the study period. The vast majority of patients received cyclophosphamide, methotrexate, and fl uorouracil (n = 2119) or cyclophosphamide, epirubicin, and fl uorouracil (CEF) (n = 2508), including seven to nine cycles of epirubicin at 60 mg/m 2 ; or dose-escalated CEF, and none received adjuvant taxanes. We therefore cannot exclude the possibility that differences between current standards and those applicable during the study period may have infl uenced the outcome of our analysis. We assume that the low-risk group included only a few patients with HER2-positive tumors, whose prognosis is likely to be worse than average. It is therefore not likely that knowledge of HER2 status would have changed the outcome.
Based on a cohort of more than 15 000 breast cancer patients, our results do not support that lymphovascular invasion has sufficient independent prognostic infl uence to move patients from a low-risk group to a high-risk group. However, lymphovascular invasion was consistently associated with reduced invasive diseasefree interval and overall survival, regardless of other tumor and treatment characteristics in the high-risk group.
